<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701607</url>
  </required_header>
  <id_info>
    <org_study_id>COPDL1</org_study_id>
    <nct_id>NCT03701607</nct_id>
  </id_info>
  <brief_title>Effect of Chemotherapy on PD-L1 in NSCLC</brief_title>
  <official_title>Effect of Platinum-based Chemotherapy on PD-L1 Expression in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baodong Qin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in
      advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that
      chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as
      Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy
      could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune
      reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced
      NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving
      chemotherapy in advanced NSCLC patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with PD-L1 positive as assessed by immunohistochemical assay</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>PD-L1 will be calculated using immunohistochemical assay</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chemotherapy</condition>
  <condition>Immunotherapy</condition>
  <condition>PD-L1</condition>
  <arm_group>
    <arm_group_label>PD-L1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PD-L1 group</intervention_name>
    <description>PD-L1 expression is evaluated using immunohistochemical assay</description>
    <arm_group_label>PD-L1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced NSCLC without druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced NSCLC diagnosed histologically; Expected survival ≥ 6 month;

          -  Without Druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc)

          -  ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥
             90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of
             normal (ULN); Liver ALT and AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 ×
             ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min

        Exclusion Criteria:

          -  Patient can not comply with research program requirements or follow-up;

          -  Patient will receive immunotherapy;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Dong Jiao, MD</last_name>
      <phone>+86-13817797639</phone>
      <email>pulava@139.com</email>
    </contact>
    <investigator>
      <last_name>Yuansheng Zang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>October 8, 2018</last_update_submitted>
  <last_update_submitted_qc>October 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Baodong Qin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

